MediWound reports Q3 EPS (24c), consensus (44c)

Reports Q3 revenue $4.8M, consensus $4.74M. “This quarter marks a pivotal period for us, with significant achievements that set the stage for consistent future revenue growth. NexoBrid was successfully launched in two key markets, the U.S. and Japan, enhancing our global footprint. In Europe, the potential expansion of the pediatric indication and our recent partnership with PolyMedics Innovations are key drivers for increased sales,” said Ofer Gonen, CEO of MediWound. “Global conflicts have also escalated the demand for NexoBrid: We have secured funding from the U.S. Department of Defense to develop field-care burn treatment for the U.S. Army; The entire non-U.S. NexoBrid inventory has been deployed to successfully treat those affected by the war in Israel. The successful outcomes in the field catalyzed additional interest from various governments. We have therefore prioritized our resources to meet the increased demand. Looking ahead, preparations for the Phase III study of EscharEx are progressing, with an updated protocol shaped by U.S. Food & Drug Administration and European Medicines Agency guidance. Anticipated enrollment is set to begin in the second half of 2024. A new collaboration with industry leader, 3M Healthcare, further validates EscharEx’s anticipated impact on the wound care market,” concluded Ofer Gonen.